Form 4: Immunome Inc. Executive Acquires 190,000 Stock Options
SEC Form 4 Filing
Immunome Inc.'s Chief Scientific Officer, Jack Higgins, acquired 190,000 stock options on August 9, 2024, at an exercise price of $12.92.
Summary
- Jack Higgins, Chief Scientific Officer of Immunome Inc., filed a Form 4 on August 13, 2024, reporting a transaction.
- On August 9, 2024, Higgins acquired 190,000 stock options with an exercise price of $12.92.
- These options vest over time, with 25% vesting on August 9, 2025, and the remainder vesting monthly over the following three years.
- The options expire on August 8, 2034.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine disclosure of stock option grants to an executive. While it can signal confidence, it's a standard part of compensation.
Positives
- The acquisition of stock options by a key executive could signal confidence in the company's future prospects.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track executive compensation and potential alignment of interests.
Stakeholder Impact
- The stock option grant aligns the executive's interests with those of the shareholders, incentivizing them to increase the company's value.
Key Dates
| Date | Description |
|---|---|
| 08/09/2024 | Date of stock option acquisition. |
| 08/09/2025 | 25% of the acquired stock options vest. |
| 08/08/2034 | Expiration date of the stock options. |
| 08/13/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.